Farletuzumab ecteribulin
As of the edition of 20 October 2026, Farletuzumab ecteribulin is an antibody drug conjugate: in active development; acts on FOLR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody drug conjugate
- Registered trials
- 4, 1 stopped early
- Disease areas
- Cancer; Lungs and airways; Hormones; Pregnancy and women's health; Urinary and reproductive; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Farletuzumab ecteribulin.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FOLR1 | Folate receptor alpha | P15328 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 1 | 1 | 1 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eisai | Lead sponsor of trials | 2017 to now |
| Bristol Myers Squibb | Lead sponsor of trials | 2022 to now |